Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TT6B75U)

• DTT Name: ABL messenger RNA (ABL mRNA) DTT Info
• Gene Name: ABL1

Molecule-Related Drug & Molecule List

1 Discontinued Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
G-1128	DMHOMFK	Chronic myelogenous leukaemia	2A20.0	Discontinued in Phase 2	[1]

5 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
GNF-5	DMGLIPV	Discovery agent	N.A.	Investigative	[2]
PMID21561767C8h	DMABZH6	Discovery agent	N.A.	Investigative	[3]
PMID23441572C24	DMG4MLA	Discovery agent	N.A.	Investigative	[4]
PMID24900538C2c	DM5PATM	Discovery agent	N.A.	Investigative	[5]
PP121	DMU8KTO	Discovery agent	N.A.	Investigative	[6]

References

• [1] Pharmaceutical Design And Development: A Molecular Biology Approach, T V Ramabhadran, 2005. Page(219).
• [2] Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors. Nature. 2010 Jan 28;463(7280):501-6.
• [3] Discovery of 5-(arenethynyl) hetero-monocyclic derivatives as potent inhibitors of BCR-ABL including the T315I gatekeeper mutant. Bioorg Med Chem Lett. 2011 Jun 15;21(12):3743-8.
• [4] Rapid discovery of a novel series of Abl kinase inhibitors by application of an integrated microfluidic synthesis and screening platform. J Med Chem. 2013 Apr 11;56(7):3033-47.
• [5] Discovery of Disubstituted Imidazo[4,5-b]pyridines and Purines as Potent TrkA Inhibitors. ACS Med Chem Lett. 2012 Jul 26;3(9):705-9.
• [6] Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat Chem Biol. 2008 Nov;4(11):691-9.